Lenalidomide Krka d.d.

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Patient Information leaflet Patient Information leaflet (PIL)
10-07-2023
Summary of Product characteristics Summary of Product characteristics (SPC)
10-07-2023
Public Assessment Report Public Assessment Report (PAR)
10-07-2023

Active ingredient:

lenalidomide hydrochloride hydrate

Available from:

Krka, d.d., Novo mesto 

ATC code:

L04AX04

INN (International Name):

lenalidomide

Therapeutic group:

Immunosoppressanti

Therapeutic area:

Multiple Myeloma; Lymphoma, Follicular; Myelodysplastic Syndromes

Therapeutic indications:

Multiple myelomaLenalidomide Krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) huwa indikat għall-kura ta ' pazjenti adulti li ma kienux ikkurati qabel mjeloma multipla li mhumiex eliġibbli għal trapjant tal -. Lenalidomide Krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Follicular lymphomaLenalidomide Krka d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Product summary:

Revision: 2

Authorization status:

Irtirat

Authorization date:

2021-02-11

Patient Information leaflet

                                86
B. FULJETT TA’ TAGĦRIF
Prodott mediċinali li m’għadux awtorizzat
87
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
LENALIDOMIDE KRKA D.D. 2.5 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 5 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 7.5 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 10 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 15 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 20 MG KAPSULI IBSIN
LENALIDOMIDE KRKA D.D. 25 MG KAPSULI IBSIN
lenalidomide
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Lenalidomide Krka d.d. u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Lenalidomide Krka d.d.
3.
Kif għandek tieħu Lenalidomide Krka d.d.
4.
Effetti sekondarji possibbli
5.
Kif taħżen Lenalidomide Krka d.d.
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU LENALIDOMIDE KRKA D.D. U GЋALXIEX JINTUŻA
X’INHU LENALIDOMIDE KRKA D.D.
Lenalidomide Krka d.d. fih is-sustanza attiva ‘lenalidomide’. Din
il-mediċina tappartjeni għal grupp
ta’ mediċini li jaffettwaw kif is-sistema immuni tiegħek taħdem.
GĦALXIEX JINTUŻA LENALIDOMIDE KRKA D.D.
Lenalidomide Krka d.d. jintuża fl-adulti għal:
-
Majeloma multipla
-
Sindromi majelodisplastiċi
-
Limfoma follikulari
MAJELOMA MULTIPLA
Majeloma multipla hi tip ta’ kanċer li jaffettwa ċertu tip ta’
ċellula tad-demm bajda, imsejħa ċ-ċellula
tal-plażma. Dawn iċ-ċelluli jinġabru fil-mudullun u jiddividu, bla
kontroll. Dan jista’ jagħmel ħsara
                                
                                Read the complete document

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
Prodott mediċinali li m’għadux awtorizzat
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Lenalidomide Krka d.d. 2.5 mg kapsuli ibsin
Lenalidomide Krka d.d. 5 mg kapsuli ibsin
Lenalidomide Krka d.d. 7.5 mg kapsuli ibsin
Lenalidomide Krka d.d. 10 mg kapsuli ibsin
Lenalidomide Krka d.d. 15 mg kapsuli ibsin
Lenalidomide Krka d.d. 20 mg kapsuli ibsin
Lenalidomide Krka d.d. 25 mg kapsuli ibsin
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull kapsula iebsa fiha lenalidomide hydrochloride monohydrate
ekwivalenti għal 2.5 mg, 5 mg, 7.5 mg,
10 mg, 15 mg, 20 mg jew 25 mg ta’ lenalidomide.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Kapsula iebsa (kapsula)
Lenalidomide Krka d.d. 2.5 mg kapsuli ibsin
L-għatu tal-kapsula huwa aħdar, il-korp tal-kapsula huwa aħdar
b’marka sewda ta’ 2.5 stampata fuqu. Il-
kontenut tal-kapsula huwa trab abjad għal isfar bajdani jew għal
kannella bajdani. Daqs tal-kapsula iebsa: 4,
tul 14 ± 1 mm.
Lenalidomide Krka d.d. 5 mg kapsuli ibsin
L-għatu tal-kapsula huwa blu, il-korp tal-kapsula huwa blu b’marka
sewda ta’ 5 stampata fuqu. Il-kontenut
tal-kapsula huwa trab abjad għal isfar bajdani jew għal kannella
bajdani. Daqs tal-kapsula iebsa: 2, tul 18 ± 1
mm.
Lenalidomide Krka d.d. 7.5 mg kapsuli ibsin
L-għatu tal-kapsula huwa kannella, il-korp tal-kapsula huwa kannella
b’marka bajda ta’ 7.5 stampata fuqu.
Il-kontenut tal-kapsula huwa trab abjad għal isfar bajdani jew għal
kannella bajdani. Daqs tal-kapsula iebsa:
1, tul 19 ± 1 mm.
Lenalidomide Krka d.d. 10 mg kapsuli ibsin
L-għatu tal-kapsula huwa aħdar, il-korp tal-kapsula huwa kannella
b’marka bajda ta’ 10 stampata fuqu.
Il-kontenut tal-kapsula huwa trab abjad għal isfar bajdani jew għal
kannella bajdani. Daqs tal-kapsula iebsa:
0, tul 21 ± 1 mm.
Lenalidomide Krka d.d. 15 mg kapsuli ibsin
L-għatu tal-kapsula huwa kannella, il-korp tal-kapsula huwa blu
b’marka sewda ta’ 15 stampata fuqu.
Il-kontenut tal-kapsula huwa trab abjad għa
                                
                                Read the complete document

Similar products

Active ingredient lenalidomide hydrochloride hydrate

lenalidomide hydrochloride hydrate

ATC code L04AX04

L04AX04

Marketed by Krka, d.d., Novo mesto 

Krka, d.d., Novo mesto 

INN (International Name) lenalidomide

lenalidomide

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-07-2023
Public Assessment Report Public Assessment Report Bulgarian 10-07-2023
Patient Information leaflet Patient Information leaflet Spanish 10-07-2023
Summary of Product characteristics Summary of Product characteristics Spanish 10-07-2023
Public Assessment Report Public Assessment Report Spanish 10-07-2023
Patient Information leaflet Patient Information leaflet Czech 10-07-2023
Summary of Product characteristics Summary of Product characteristics Czech 10-07-2023
Public Assessment Report Public Assessment Report Czech 10-07-2023
Patient Information leaflet Patient Information leaflet Danish 10-07-2023
Summary of Product characteristics Summary of Product characteristics Danish 10-07-2023
Public Assessment Report Public Assessment Report Danish 10-07-2023
Patient Information leaflet Patient Information leaflet German 10-07-2023
Summary of Product characteristics Summary of Product characteristics German 10-07-2023
Public Assessment Report Public Assessment Report German 10-07-2023
Patient Information leaflet Patient Information leaflet Estonian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Estonian 10-07-2023
Public Assessment Report Public Assessment Report Estonian 10-07-2023
Patient Information leaflet Patient Information leaflet Greek 10-07-2023
Summary of Product characteristics Summary of Product characteristics Greek 10-07-2023
Public Assessment Report Public Assessment Report Greek 10-07-2023
Patient Information leaflet Patient Information leaflet English 10-07-2023
Summary of Product characteristics Summary of Product characteristics English 10-07-2023
Public Assessment Report Public Assessment Report English 10-07-2023
Patient Information leaflet Patient Information leaflet French 10-07-2023
Summary of Product characteristics Summary of Product characteristics French 10-07-2023
Public Assessment Report Public Assessment Report French 10-07-2023
Patient Information leaflet Patient Information leaflet Italian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Italian 10-07-2023
Public Assessment Report Public Assessment Report Italian 10-07-2023
Patient Information leaflet Patient Information leaflet Latvian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Latvian 10-07-2023
Public Assessment Report Public Assessment Report Latvian 10-07-2023
Patient Information leaflet Patient Information leaflet Lithuanian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-07-2023
Public Assessment Report Public Assessment Report Lithuanian 10-07-2023
Patient Information leaflet Patient Information leaflet Hungarian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 10-07-2023
Public Assessment Report Public Assessment Report Hungarian 10-07-2023
Patient Information leaflet Patient Information leaflet Dutch 10-07-2023
Summary of Product characteristics Summary of Product characteristics Dutch 10-07-2023
Public Assessment Report Public Assessment Report Dutch 10-07-2023
Patient Information leaflet Patient Information leaflet Polish 10-07-2023
Summary of Product characteristics Summary of Product characteristics Polish 10-07-2023
Public Assessment Report Public Assessment Report Polish 10-07-2023
Patient Information leaflet Patient Information leaflet Portuguese 10-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 10-07-2023
Public Assessment Report Public Assessment Report Portuguese 10-07-2023
Patient Information leaflet Patient Information leaflet Romanian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Romanian 10-07-2023
Public Assessment Report Public Assessment Report Romanian 10-07-2023
Patient Information leaflet Patient Information leaflet Slovak 10-07-2023
Summary of Product characteristics Summary of Product characteristics Slovak 10-07-2023
Public Assessment Report Public Assessment Report Slovak 10-07-2023
Patient Information leaflet Patient Information leaflet Slovenian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 10-07-2023
Public Assessment Report Public Assessment Report Slovenian 10-07-2023
Patient Information leaflet Patient Information leaflet Finnish 10-07-2023
Summary of Product characteristics Summary of Product characteristics Finnish 10-07-2023
Public Assessment Report Public Assessment Report Finnish 10-07-2023
Patient Information leaflet Patient Information leaflet Swedish 10-07-2023
Summary of Product characteristics Summary of Product characteristics Swedish 10-07-2023
Public Assessment Report Public Assessment Report Swedish 10-07-2023
Patient Information leaflet Patient Information leaflet Norwegian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 10-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 10-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 10-07-2023
Patient Information leaflet Patient Information leaflet Croatian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Croatian 10-07-2023
Public Assessment Report Public Assessment Report Croatian 10-07-2023

Search alerts related to this product

Alerts Lenalidomide Krka d.d. hydrochloride hydrate

Lenalidomide Krka d.d. hydrochloride hydrate

View documents history

Documents history Documents history

Lenalidomide Krka d.d.